- Case Report
- Open Access
A male presenting with a primary mucinous bladder carcinoma: a case report
© Sigalas et al; licensee BioMed Central Ltd. 2010
- Received: 19 September 2009
- Accepted: 3 February 2010
- Published: 3 February 2010
The primary mucinous adenocarcinoma of the bladder is an extremely rare urologic entity, which is found in less than 2% of all urinary bladder tumours and is often presented as metastatic.
A 69-year old male patient was diagnosed with a primary mucinous adenocarcinoma of the bladder after undergoing a transurethral resection of a bladder tumour and complete examination of the entire gastrointestinal tract to rule out other primary cites. Immunohistochemistry confirmed the nature of the tumour. The patient underwent a radical cystoprostatectomy with en block bilateral pelvic lymphadenectomy and urinary diversion with a Bricker ileostomy.
The primary adenocarcinoma creates a diagnostic dilemma, since it cannot be easily differentiated by the adenocarcinoma that originates from the colon and the prostate. We advocate the radical surgical management, after exclusion of any primary malignant sites related to the gastrointestinal tract. The immunohistochemistry has a leading role, assisting with the differential diagnosis.
- Urinary Bladder
- Intestinal Metaplasia
- Urinary Diversion
- Mucinous Adenocarcinoma
- Urothelial Neoplasm
Urinary bladder cancer is the second most frequent tumour of the genitourinary tract . Adenocarcinomas account for less than 2% of all bladder cancers . One of the most common forms of adenocarcinoma of the bladder is the metastatic adenocarcinoma. The primary sites for these tumours include the rectum, stomach, endometrium, breast, prostate, and ovaries. We present such a case, providing a meticulous review of the current literature.
The specimen of radical cystoprostatectomy included the urinary bladder with pericystic fatty tissue and the prostate gland. On section, a tumour was identified, measuring in the greatest dimension 3 cm. The tumour was localized in the posterior bladder wall and had an exophytic growth pattern with solid (nodular) appearance. It seemed to invade the wall of the bladder, extending to the proximal urethral margin of the prostate.
Histological and immunohistochemical features
The majority of primary adenocarcinomas of the urinary bladder (50-60%) arise at the bladder base and almost all of the remaining are associated with urachal remnants . The male to female ratio of non-urachal neoplasms approaches 3 to 1, in contrast to almost 1 to 1 for urachal tumours. Most patients are middle-aged (mean, approximately 62 years). Many experts suggest that adenocarcinomas arise through a process of intestinal metaplasia stimulated by chronic irritation. Among other factors associated with urothelial adenocarcinoma, exstrophy and persistent urachal remnants are the most common. Adenocarcinomas arising in areas of urachal remnants differ clinically from those occurring at the bladder base, but these neoplasms are similar in their pathology and behavior.
Hematuria is the most common presenting sign, manifested in about 90% of patients. Almost half of the patients complain about dysuria, nocturia, frequency and pain. Cystoscopically, bladder adenocarcinomas ordinarily appear as single, nodular tumours that can not be reliably distinguished from urothelial neoplasms.
Adenocarcinomas of the urinary bladder, regardless of site, include the following histologic variations: 1) Adenocarcinoma non otherwise specified, 2) Adenocarcinoma of enteric type, 3) Adenocarcinoma with signet-ring cells, 4) Mucinous adenocarcinoma, 5) Clear cell adenocarcinoma, 6) Hepatoid adenocarcinoma, 7) Mixed adenocarcinoma . The usual malignant tumour is a well-to-moderately differentiated adenocarcinoma, secreting variable amounts of mucin. The tumour cells represent a combination of columnar and goblet cells .
Mucinous adenocarcinoma of the urinary bladder includes large lakes of extracellular mucin mixed with collections of tumour cells. By definition, these mucinous foci should constitute at least half of the tumour mass. In some cases, there is an admixture of extracellular and intracellular mucin; the latter is resulting in signet ring configuration .
Regarding immunohistochemistry, adenocarcinoma of the urinary bladder expresses CEA, CDX-2, MUC-1, MUC-2 and MUC-3, same as colonic adenocarcinoma. Cytokeratins 7 and 20 are positive, in contrast with colonic adenocarcinoma that expresses cytokeratin 20 but not cytokeratin 7 .
The differential diagnosis includes metastatic colonic adenocarcinoma, urothelial neoplasms with glandular differentiation, intestinal metaplasia and nephrogenic metaplasia. Metastatic adenocarcinoma is differentiated using the immunophenotype (CK7 negative and CK 20 positive). Urothelial neoplasm with glandular differentiation may contain intracellular and luminal mucins; however, mucins are not abundant. In addition, in this type of carcinoma, signet-ring cells are not prominent and the "glands" are surrounded by pseudostratified epithelium. Intestinal metaplasia may infiltrate the lamina propria or even the bladder wall. Mucinous lakes are not uncommon in these cases and their presence in a tissue sample is diagnostic of adenocarcinoma only with the presence of neoplastic cells. The cells of intestinal metaplasia lack nuclear anaplasia and rarely involve the muscularis propria. Nodular areas of cystitis glandularis rich in goblet cells should be considered benign, even if the nodules extend into the lamina propria.
Prognosis varies with stage, with survival approaching 75-100% among patients whose tumours are confined to the urinary bladder. Unfortunately, low-stage cancers account for fewer than 30% of reported cases . Patients with urachal tumours tend to have a better short-term survival rate than those with nonurachal cancers .
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Grossfeld GD, Carroll PR: Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am. 1998, 25: 661-676. 10.1016/S0094-0143(05)70055-0.View ArticlePubMedGoogle Scholar
- Dahm P, Gschwend JE: Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003, 44: 672-681. 10.1016/S0302-2838(03)00416-0.View ArticlePubMedGoogle Scholar
- Mazzucchelli R, Scarpelli M, Montironi R: Mucinous adenocarcinoma with superficial stromal invasion and adenoma of urachal remnants: a case report. J Clin Pathol. 2003, 56: 465-467. 10.1136/jcp.56.6.465.PubMed CentralView ArticlePubMedGoogle Scholar
- Eble JN, Epstein JI, Seternhenn IA: World Health Organization Classification of Tumours. Pathology and Genetics, Tumours of the Urinary System and Male Genital track. 2004, Lyon: IARC Press, 128-132.Google Scholar
- Murphy WM, Grignon DJ, Periman EJ: Tumors of the Kidney, Bladder and Related Urinary Structures. American Registry of Pathology, New York. 2004, 304-309. 4Google Scholar
- Marques ML, D'Alessandro GS, Chade DC, Lanzoni VP, Saiovici S, Ramos de Almeida JR: Primary mucinous adenocarcinoma of the bladder with signet-ring cells: case report. Sao Paulo Med J. 2007, 125: 297-299. 10.1590/S1516-31802007000500011.View ArticlePubMedGoogle Scholar
- Bostwick DG, Cheng L: Urologic Surgical Pathology. Adenocarcinoma of the Urinary Bladder. 2008, Elsevier, New York, 300-302.Google Scholar
- Werling RW, Yaziji H, Bacchi CE, Gown AM: CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. AJSP. 2003, 27: 303.Google Scholar
- Stenhouse G, Mcrae D, Pollock AM: Urachal adenocarcinoma in situ with pseudomyxoma peritonei: a case report. J Clin Pathol. 2003, 56: 152-153. 10.1136/jcp.56.2.152.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.